Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease
Sotagliflozin is a cost-effective adjunct to insulin therapy for T1D and CKD patients, providing clinical benefits and falling below the $150,000/QALY willingness-to-pay threshold in 59% of probabilistic sensitivity analysis simulations.
Authors
- Slaven Sikirica
- Jason Shafrin (ORCID: https://orcid.org/0000-0001-8444-5979)
- Moises Marin
- Mariam Anderson
- Shanshan Wang (ORCID: https://orcid.org/0009-0007-3503-0161)
- Jae‐Hong Kim (ORCID: https://orcid.org/0000-0002-8019-0208)
Institutions
- Lexicon Pharmaceuticals (United States) (US)
- Center For Policy Research (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-06-27
- DOI
- https://doi.org/10.18553/jmcp.2025.31.7.641
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.59